The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

Multiple Myeloma, Version 1.2013

(2017) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease

(2015) J. Paton-Hough et al.   BONE

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

(2014) Shuji Ozaki et al.   ACTA HAEMATOLOGICA

Modulation of NRF2 signaling pathway by nuclear receptors: Implications for cancer

(2014) Akhileshwar Namani et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Nrf2, a Regulator of the Proteasome, Controls Self-Renewal and Pluripotency in Human Embryonic Stem Cells

(2014) Jiwon Jang et al.   STEM CELLS

RARAfusion genes in acute promyelocytic leukemia: a review

(2014) Etienne De Braekeleer et al.   Expert Review of Hematology

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

(2013) M. Wang et al.   BLOOD

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

(2013) Samantha Pozzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

(2013) Robert Z. Orlowski   CANCER CELL

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

(2013) R. Niesvizky et al.   CLINICAL CANCER RESEARCH

The emerging role of the Nrf2-Keap1 signaling pathway in cancer

(2013) M. C. Jaramillo et al.   GENES & DEVELOPMENT

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

(2013) C C Bjorklund et al.   LEUKEMIA

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Sequence analysis of  -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

(2012) D. I. Lichter et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Nrf2-dependent Induction of Proteasome and Pa28αβ Regulator Are Required for Adaptation to Oxidative Stress

(2012) Andrew M. Pickering et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents

(2012) Sadagopan Magesh et al.   MEDICINAL RESEARCH REVIEWS

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha

(2012) B. N. Chorley et al.   NUCLEIC ACIDS RESEARCH

New Proteasome Inhibitors in Myeloma

(2012) Panisinee Lawasut et al.   Current Hematologic Malignancy Reports

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

(2011) I. Hrusovsky et al.   ONCOLOGY

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

A Novel Testis-specific GTPase Serves as a Link to Proteasome Biogenesis: Functional Characterization of RhoS/RSA-14-44 in Spermatogenesis

(2010) Ning Zhang et al.   MOLECULAR BIOLOGY OF THE CELL

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

(2010) Senthil K. Radhakrishnan et al.   MOLECULAR CELL

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Catalytic Mechanism and Assembly of the Proteasome

(2009) António J. Marques et al.   CHEMICAL REVIEWS

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02

(2009) S. LÜ et al.   International Journal of Laboratory Hematology

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

(2009) Jacob P. Laubach et al.   LEUKEMIA & LYMPHOMA

Molecular mechanisms of proteasome assembly

(2009) Shigeo Murata et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE